RedHill Biopharma Ltd (RDHL)

[midastouch017]

RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

GlobeNewswire GlobeNewswire•April 2, 2020

RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo®
Movantik® generated U.S. net sales of $96 million in 2019
TEL-AVIV, Israel and RALEIGH, N.C., April 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that it has completed the recently announced acquisition of the global rights, excluding Europe, Canada and Israel, to Movantik® (naloxegol)1, for the treatment of opioid-induced constipation (OIC)2 from AstraZeneca (LSE/STO/NYSE: AZN).
“We are expanding the promotion of Movantik® with our current sales force of approximately 100 sales representatives. Given the excellent work that AstraZeneca has done to date, we expect a smooth transition of all commercial activities. We are excited for the opportunity to grow the call points for Movantik® and offer more patients this preferred treatment for opioid-induced constipation,” said Rick Scruggs, Chief Commercial Officer of RedHill.

https://finance.yahoo.com/news/redhill-biopharma-completes-acquisition-movantik-110010570.html